Literature DB >> 16545884

Melittin analogs with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes.

Sabine Boeckle1, Julia Fahrmeir, Wolfgang Roedl, Manfred Ogris, Ernst Wagner.   

Abstract

Melittin-polyethylenimine (PEI) conjugates have been shown to enhance gene transfer efficiency of polyplexes due to their membrane-destabilizing properties. Inherent lytic activity at neutral pH however also provokes high cytotoxicity due to plasma membrane damage. In order to shift the lytic activity towards the endosomal membrane, several melittin analogs were designed. Acidic modification of melittin by replacing neutral glutamines (Gln-25 and Gln-26) with glutamic acid residues greatly improved the lytic activity of C-terminally linked PEI conjugates at the endosomal pH of 5. This activity correlated well with the gene transfer efficiency of polyplexes in four different cell lines. Melittin-PEI conjugates with high lytic activities at endosomal pH were then incorporated into EGF receptor-targeted and polyethylene glycol-shielded polyplexes. The resulting particles had virus-like dimension (150 nm) with a neutral surface charge and were subsequently purified by size exclusion chromatography to remove unbound toxic PEI conjugate. These purified polyplexes mediated EGF-receptor-specific gene transfer with up to 70-fold higher activity compared to the corresponding PEI polyplexes without melittin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545884     DOI: 10.1016/j.jconrel.2006.02.002

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  26 in total

1.  Reactive and bioactive cationic α-helical polypeptide template for nonviral gene delivery.

Authors:  Nathan P Gabrielson; Hua Lu; Lichen Yin; Dong Li; Fei Wang; Jianjun Cheng
Journal:  Angew Chem Int Ed Engl       Date:  2011-12-07       Impact factor: 15.336

Review 2.  Nonviral gene delivery: what we know and what is next.

Authors:  Xiang Gao; Keun-Sik Kim; Dexi Liu
Journal:  AAPS J       Date:  2007-03-23       Impact factor: 4.009

Review 3.  Peptide-guided gene delivery.

Authors:  Molly E Martin; Kevin G Rice
Journal:  AAPS J       Date:  2007-02-09       Impact factor: 4.009

Review 4.  Strategies to improve drug delivery across the blood-brain barrier.

Authors:  Albertus G de Boer; Pieter J Gaillard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 5.  Nanoparticle interaction with biological membranes: does nanotechnology present a Janus face?

Authors:  Pascale R Leroueil; Seungpyo Hong; Almut Mecke; James R Baker; Bradford G Orr; Mark M Banaszak Holl
Journal:  Acc Chem Res       Date:  2007-05-03       Impact factor: 22.384

Review 6.  Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems.

Authors:  Sabine Boeckle; Ernst Wagner
Journal:  AAPS J       Date:  2006       Impact factor: 4.009

Review 7.  Single-particle tracking as a quantitative microscopy-based approach to unravel cell entry mechanisms of viruses and pharmaceutical nanoparticles.

Authors:  Nadia Ruthardt; Don C Lamb; Christoph Bräuchle
Journal:  Mol Ther       Date:  2011-06-07       Impact factor: 11.454

8.  Computational design and experimental characterization of peptides intended for pH-dependent membrane insertion and pore formation.

Authors:  Yao Zhang; René Bartz; Gevorg Grigoryan; Michael Bryant; Jeff Aaronson; Stephen Beck; Nathalie Innocent; Lee Klein; William Procopio; Tom Tucker; Vasant Jadhav; David M Tellers; William F DeGrado
Journal:  ACS Chem Biol       Date:  2015-01-28       Impact factor: 5.100

9.  Synthesis and in vitro testing of new potent polyacridine-melittin gene delivery peptides.

Authors:  Nicholas J Baumhover; Kevin Anderson; Christian A Fernandez; Kevin G Rice
Journal:  Bioconjug Chem       Date:  2010-01       Impact factor: 4.774

10.  Targeting the EGF receptor for ovarian cancer therapy.

Authors:  Reema Zeineldin; Carolyn Y Muller; M Sharon Stack; Laurie G Hudson
Journal:  J Oncol       Date:  2009-12-28       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.